Search

Researchers at Baskent University Faculty of Medicine conducted a retrospective study on Crohn's disease, focusing on the clinical characteristics and etiology of terminal ileum ulcers. The study aimed to investigate the underlying causes of terminal ileal ulcers detected during colonoscopies and analyze their clinical, endoscopic, and histopathological characteristics. Findings revealed that not all terminal ileal ulcers are indicative of Crohn's disease, with only 16.6% of patients diagnosed with CD, while the majority had nonspecific ulcers. The study suggests that repetitive colonoscopies should be reconsidered in cases with active ileitis. [Extracted from the article]

A recent study conducted at the University of Colorado in Aurora, Colorado, explored the impact of the intestinal microbiome on inflammation in aged mice after burn injuries. The researchers found that aged burn injured mice had an unhealthy balance of bacteria in their feces, which coincided with increased inflammation in the intestines and lungs. However, when aged mice were housed with younger mice, their microbiome shifted to a healthier state and inflammation was reduced. These findings suggest that the intestinal microbiome plays a crucial role in mediating inflammation and could potentially lead to new treatments in the future. [Extracted from the article]

A recent preprint abstract from biorxiv.org discusses the role of sphingosine 1-phosphate receptor-1 (S1PR1) in regulating lymphatic valve development and preventing the formation of tertiary lymphoid organs (TLOs) in the terminal ileum. The study found that the deletion of S1PR1 from lymphatic endothelial cells (LECs) resulted in fewer lymphatic valves and dysfunctional LVs in the terminal ileum. TLOs, which are associated with ileitis, formed in this location. However, mice lacking S1PR1 did not show obvious signs of ileitis. The study also suggests that TLOs may be a sign of subclinical inflammation due to lymphatic disorders in the absence of ileitis. [Extracted from the article]

A recent study from the University of Campania Luigi Vanvitelli in Italy explores the effectiveness of small molecules in treating inflammatory pouch disorders following ileal pouch-anal anastomosis (IPAA) for ulcerative colitis (UC). The researchers found that while biological therapies have shown promise, there is a need for more robust randomized clinical trials. Preliminary studies suggest that Janus kinase (JAK) inhibitors and sphingosine-1-phosphate receptor (S1P-R) modulators, such as Tofacitinib, may be effective in treating chronic pouchitis. However, further evaluation is needed for other small molecules like Upadacitinib, Filgotinib, and ozanimod. The study emphasizes the importance of high-quality studies and real-world registries to develop guidelines for advanced therapies in post-IPAA inflammatory disorders. [Extracted from the article]

Researchers from Case Western Reserve University have conducted a study on the potential anti-inflammatory properties of pentadecanoic acid (C15:0) in inflammatory bowel disease (IBD). The study used mouse models of IBD and found that C15:0 supplementation had an anti-inflammatory effect, reducing the severity of ileitis and colitis, as well as preserving gut integrity and alleviating colitis signs. The findings suggest that C15:0 may have therapeutic effects in the treatment of IBD and could have translational potential for humans. Further research is needed to explore this potential treatment option. [Extracted from the article]

A study conducted by researchers at Shiraz University of Medical Sciences in Iran provides an update on the understanding of pouchitis, a common complication after ileal pouch-anal anastomosis (IPAA). The study highlights the need for further research and knowledge in the treatment of pouchitis, which can significantly impact patients' quality of life. The researchers discuss various diagnostic criteria and therapeutic approaches, including antibiotics, probiotics, anti-tumor necrosis factor drugs, dietary changes, and complementary and alternative medicine. They emphasize the importance of well-designed studies to determine the optimal treatment for pouchitis. [Extracted from the article]

The article details research from Shamir (Assaf Harofeh) Medical Center on developing a predictive model to distinguish Crohn's disease (CD) from other causes of acute terminal ileitis. Topics discussed include the study's methodology involving a logistic regression model, key predictors such as age and platelet counts, and the model's diagnostic performance with high sensitivity and moderate specificity.

A clinical trial, NCT06551194, has been launched to investigate the prevalence and risk factors of difficult-to-treat inflammatory bowel disease (DTT-IBD). The study will be conducted retrospectively in two large tertiary care centers in Milan, Italy, using the International Organisation for the Study of IBD (IOIBD) criteria. The aim is to standardize terminology and promote research into patients who require new treatments. The study is currently recruiting adult patients diagnosed with Crohn's disease or ulcerative colitis, with the primary outcome measure expected to be collected by September 30, 2024. [Extracted from the article]

A recent study conducted by researchers at the University of North Carolina School of Medicine aimed to assess the value of histologic assessment after ileal pouch-anal anastomosis (IPAA) in patients with ulcerative colitis (UC). The study found that patients with inflammation in the pouch body had a higher likelihood of histologic inflammation compared to those without inflammation. Additionally, a subset of patients with endoscopic inflammation in the pre-pouch ileum later developed Crohn's-like disease of the pouch (CLDP). The study suggests that further research is needed to determine the added benefit of histology in assessing disease activity and the prognostic value of histologic inflammation without endoscopic inflammation. [Extracted from the article]

A recent study conducted by researchers from the University of North Carolina has found that antibiotic use in the 12 months prior to ileal pouch-anal anastomosis (IPAA) surgery increases the risk of pouchitis, the most common complication after the surgery. The study, which used a population-based cohort of patients in Denmark, found that antibiotic exposure in the year before IPAA was associated with a higher risk of pouchitis. However, nonsteroidal anti-inflammatory drug (NSAID) exposure and appendectomy were not found to be associated with the risk of pouchitis. The researchers suggest that future studies should focus on identifying specific microbial changes in at-risk patients to enable earlier interventions. [Extracted from the article]

The article focuses on a study from the University of Chicago Medicine Inflammatory Bowel Disease Center comparing clinical symptoms and the modified Pouchitis Disease Activity Index (mPDAI) among different endoscopic phenotypes in inflammatory bowel disease. Topics include the classification of seven endoscopic phenotypes, variations in mPDAI scores across these phenotypes, and the limited effectiveness of symptoms alone in distinguishing between them.

A recent study conducted at the Icahn School of Medicine at Mount Sinai in New York City examined the impact of pregnancy on the development of pouchitis in women with ulcerative colitis. Pouchitis is a condition characterized by symptoms such as increased stool frequency and urgency, which are treated with antibiotics. The study found that acute pouchitis was common during pregnancy and the postpartum period, particularly in women with a history of pouchitis. These findings suggest that microbial shifts may contribute to the development of pouchitis during pregnancy. The study highlights the need for preconception counseling to focus on the prevention and management of pouchitis in pregnant women. [Extracted from the article]

Three case reports were described in which boys aged 1-14 years exhibited lack of efficacy during treatment with anakinra or methylprednisolone for ulcerative ileitis, ulcerative colitis, or autoimmune enteropathy. In the first two cases, despite treatment with methylprednisolone, no endoscopic improvement was achieved. However, clinical improvement was observed after receiving tocilizumab. In the third case, treatment with anakinra did not result in clinical improvement, but after switching to adalimumab, clinical resolution was achieved. [Extracted from the article]

Researchers at Tianjin Medical University in China have conducted a study on pouchitis, a common complication following surgery for ulcerative colitis. The researchers created a rat model of pouchitis using microsurgery and induced inflammation in the ileal pouch using dextran sulfate sodium. They validated the success of the model through various analyses. This animal model provides a foundation for further research on the pathogenesis and treatment of pouchitis. [Extracted from the article]

A recent study conducted at Columbia University investigated the association between different surgical techniques used in patients with inflammatory bowel disease (IBD) who underwent restorative proctocolectomy with ileal pouch-anal anastomosis (IPAA). The study found that there was no significant difference in the rates of cuffitis and/or pouchitis between patients who underwent mucosectomy and those who did not. However, patients who underwent mucosectomy were more likely to develop strictures. These findings suggest that stapled anastomosis without mucosectomy may be a preferable technique. [Extracted from the article]

A recent study investigated the association between anti-integrin avb6 antibodies and the development of pouchitis in patients with ulcerative colitis (UC) who underwent restorative proctocolectomy with ileal pouch-anal anastomosis (IPAA). The study found that levels of anti-integrin avb6 antibodies were significantly decreased after RPC, but remained high in patients who developed pouchitis. The antibody levels at the time of RPC may serve as a potential prognostic biomarker for predicting the risk of pouchitis in patients with UC. However, it is important to note that this study has not yet undergone peer review. [Extracted from the article]

A recent study conducted by researchers at the University of Missouri Kansas City examined the impact of orthotopic liver transplantation (OLT) on the risk of developing pouchitis in patients with primary sclerosing cholangitis (PSC) and inflammatory bowel disease (IBD) who have undergone ileal pouch-anal anastomosis (IPAA). The study found that pouchitis is a common complication in patients with IPAA, with up to 66% of patients developing it. However, the risk of pouchitis was significantly higher in patients who had IPAA followed by OLT compared to those who had OLT followed by IPAA. The researchers suggest that further studies are needed to understand the reasons behind this difference. [Extracted from the article]

A new study conducted at the University of North Carolina Chapel Hill provides insights into the natural history of ulcerative colitis (UC) after ileal pouch-anal anastomosis (IPAA). The study aimed to identify key outcomes within 1, 3, 5, and 10 years after IPAA, including the incidence of pouchitis, Crohn's-like disease of the pouch (CLDP), use of advanced therapies, and pouch failure. The study found that the incidence of pouchitis increased from 58% in the first year after IPAA to 72% at 10 years after IPAA. Additionally, 14% of patients required advanced therapies after IPAA. These findings highlight the ongoing challenges and need for further research in managing UC after IPAA. [Extracted from the article]

A recent study conducted by researchers at George Washington University School of Medicine and Health Sciences focused on B-cell lymphoma, a type of cancer that primarily affects the digestive system. The study highlighted the case of an elderly patient from Honduras who presented with symptoms resembling Crohn's disease but was ultimately diagnosed with diffuse large B-cell lymphoma. The researchers emphasized the importance of considering a broad range of possibilities when evaluating ileitis, a condition characterized by inflammation of the ileum, and the significance of histologic sampling in diagnosis. This information may be valuable for individuals conducting research on B-cell lymphoma and related conditions. [Extracted from the article]

A recent study conducted at the Fundeni Clinical Institute in Bucharest, Romania, focused on the diagnosis and medical treatment of acute and chronic idiopathic pouchitis in inflammatory bowel disease (IBD) patients. Pouchitis is a common complication that affects up to 60% of patients who undergo proctocolectomy with ileal pouch-anal anastomosis (IPPA) for ulcerative colitis (UC). While acute cases of pouchitis typically respond well to antibiotics, about 15% of patients develop a refractory disease that requires advanced immunosuppressive therapies. The study found limited data on the effectiveness of different biologics or small molecules for managing chronic idiopathic pouchitis, with vedolizumab being the only biologic agent approved for treatment. The research concluded that recommendations for managing these conditions are based on small studies and case series, resulting in low to very low certainty of evidence. [Extracted from the article]

A patent application has been submitted for a potential treatment for chronic pouchitis, a condition that affects a significant percentage of patients who have undergone a specific surgical procedure. The cause of pouchitis is believed to be a combination of factors, including exposure to harmful components of feces and immune system dysfunction. Current treatments have had mixed success, so there is a need for more effective therapies. The patent application proposes the use of an anti-a4b7 integrin antibody called vedolizumab, which would be administered to patients with chronic pouchitis to achieve remission and improve symptoms and quality of life. The application provides detailed information on the specific antibody sequences and dosing regimens used in the proposed treatment. [Extracted from the article]

A recent study conducted at Tanta University in Egypt investigated the effect of curcumin on indomethacin-induced ileitis in rats. Ileitis is a condition characterized by inflammation of the intestine. The researchers found that curcumin, a component of turmeric, had anti-inflammatory and antioxidant effects and could decrease ileitis in rats. This suggests that curcumin may be a potential treatment for intestinal injury. Further research is needed to explore its effectiveness in humans. [Extracted from the article]

A recent study conducted by researchers at Beth Israel Deaconess Medical Center in Boston, Massachusetts, explores the causes and treatment options for pouchitis, a common complication in patients with inflammatory bowel disease. The study emphasizes the importance of early and accurate diagnosis using a combination of symptoms, endoscopy, and histology. While most patients respond well to antibiotic therapy, managing chronic antibiotic-refractory pouchitis remains challenging. The researchers suggest that further longitudinal assessment of the pouch, incorporating new technologies, may help to better understand the factors driving pouchitis. [Extracted from the article]

A 73-year-old woman developed chronic ileitis while being treated with rituximab for stage IV follicular lymphoma. She also showed resistance to prednisone and unspecified steroids during treatment for ileitis. The woman presented with fevers, bloody diarrhea, and abdominal pain, and was found to have multiple peri-anal ulcers and thickening of the distal terminal ileum. Pathology revealed chronic active ileitis, which was considered to be a side effect of rituximab. Despite treatment with steroids, the woman continued to experience symptoms and further investigation is being done to determine the appropriate course of treatment. [Extracted from the article]

A 73-year-old woman developed chronic ileitis while being treated with rituximab for stage IV follicular lymphoma. She also showed resistance to prednisone and unspecified steroids during treatment for ileitis. The woman presented with fevers, bloody diarrhea, and abdominal pain, and was found to have multiple peri-anal ulcers and thickening of the distal terminal ileum. Pathology revealed chronic active ileitis, which was considered to be a side effect of rituximab. Despite treatment with steroids, the woman continued to experience symptoms and further investigation is being done to determine the appropriate course of treatment. [Extracted from the article]

A recent study conducted at Columbia University in New York City explores the pathophysiology and management of pouchitis, an inflammatory disease of the ileal reservoir. Pouchitis commonly occurs after restorative proctocolectomy with ileal pouch-anal anastomosis, and treating chronic antibiotic-refractory pouchitis has proven to be challenging. The research highlights the multifactorial nature of pouchitis, involving factors such as genetic disposition, gut microbiota, dysregulated host immunity, surgical techniques, and ischaemia. Diagnosis and classification are crucial for effective management, and treatment options include oral antibiotics for acute pouchitis and induction and maintenance therapy with integrin, interleukin, or tumor necrosis factor inhibitors for chronic antibiotic-refractory pouchitis. Hyperbaric oxygen therapy may be beneficial for chronic pouchitis with ischaemic features, fistulae, or abscesses. [Extracted from the article]

A recent report from Barts Health NHS Trust in London, United Kingdom, discusses a case of a young girl who presented with abdominal pain and vomiting following a viral illness. Further investigations revealed inflammation in the small intestine, and endoscopy showed ulcers in the jejunum and ileum. The patient was diagnosed with Henoch-Schonlein-related ileitis, a rare complication of IgA vasculitis. Treatment with steroids led to a good recovery with no long-term effects. This case highlights the importance of multidisciplinary team management and the use of video capsule endoscopy in diagnosing and treating rare gastrointestinal manifestations of vasculitis. [Extracted from the article]

A study conducted by researchers at Sun Yat-sen University in Guangzhou, China, has investigated the effects of exposure to F-53B, a substitute for perfluorooctane sulfonic acid (PFOS), on enterohepatic toxicity in mice. The study found that F-53B caused hepatic injury, ileitis (inflammation of the ileum), and dysbiosis (imbalance) in the gut microbiota of the mice. The researchers also observed changes in gene expression related to fatty acid metabolism, inflammation, and mucosal barrier function. These findings suggest that dysbiosis of the gut microbiota may play a role in the enterohepatic toxicity induced by F-53B. [Extracted from the article]

A 61-year-old man developed Crohn's Disease (CD) while being treated with secukinumab, brodalumab, and ixekizumab for plaque psoriasis. He had a history of plaque psoriasis and had been receiving subcutaneous secukinumab for one year. He presented to the emergency department with abdominal pain and was diagnosed with small bowel obstruction secondary to terminal ileitis. After treatment with methylprednisolone and prednisone, he achieved clinical remission with resolution of abdominal pain. The man discontinued secukinumab and started on risankizumab. [Extracted from the article]

A recent study conducted at the Cleveland Clinic Foundation examined the impact of liver transplantation on patients with primary sclerosing cholangitis and inflammatory bowel disease who also underwent ileal pouch-anal anastomosis (IPAA). The study found that patients who received a liver transplant had a higher rate of chronic pouchitis compared to those who did not receive a transplant. However, overall survival and pouch survival were similar between the two groups. The timing of the liver transplant did not affect the outcomes of the IPAA procedure. The study suggests that liver transplantation does not influence short-term and long-term pouch outcomes in these patients. [Extracted from the article]

A 33-year-old patient developed terminal ileitis while being treated with tacrolimus for immunoglobulin A-related glomerulonephritis. The patient had a history of glomerulonephritis, peritoneal dialysis, and a kidney transplant. They experienced symptoms such as oral ulcers, abdominal pain, diarrhea, and weight loss. After undergoing laparoscopic ileocolic resection, the patient's condition improved and they were discharged. Follow-up colonoscopies showed the presence of small ulcers, but the patient remained asymptomatic. The patient continued to receive close follow-up care with frequent colonoscopies. [Extracted from the article]

A systematic review conducted by researchers at the Icahn School of Medicine at Mount Sinai explores the impact of dietary interventions and supplementation on patients with an ileal pouch-anal anastomosis, a surgical procedure commonly used for patients with ulcerative colitis. The review aims to provide evidence-based recommendations for dietary interventions to maintain pouch health. The researchers highlight the importance of diet in pouch function and the development of pouchitis, a common complication of the surgery. However, they note that conflicting results from multiple studies make it difficult to establish concrete dietary recommendations. [Extracted from the article]

A recent study conducted by researchers at Columbia University highlights the management of primary sclerosing cholangitis (PSC) and extraintestinal disorders in patients with ileal pouches. The study found that while restorative proctocolectomy with ileal pouch-anal anastomosis can improve the quality of life for patients with ulcerative colitis, extraintestinal manifestations such as PSC can persist after colectomy. The research reviewed the diagnosis and treatment of liver, joint, skin, and eye manifestations in patients with restorative proctocolectomy and ileal pouch-anal anastomosis. The study concluded that PSC and extraintestinal manifestations appear to be associated with inflammatory disorders of the ileal pouch, and effective therapy with biologics may benefit concurrent disorders of the joints, skin, and eyes. [Extracted from the article]

A new report discusses research findings on ulcerative colitis, specifically focusing on the management of pouchitis and inflammatory pouch disorders. The American Gastroenterological Association (AGA) has developed a clinical practice guideline to support practitioners in managing these conditions. The guideline includes recommendations for the use of antibiotics, probiotics, and advanced immunosuppressive therapies, depending on the specific symptoms and response to treatment. The research concludes that this guideline provides a comprehensive and patient-centered approach to managing patients with pouchitis and other inflammatory conditions of the pouch. [Extracted from the article]

A new report from the University of Pennsylvania discusses the management of chronic antibiotic refractory pouchitis, a condition that presents a therapeutic challenge for patients and healthcare providers. The report summarizes the current evidence regarding the management of this condition, including pharmacologic and non-pharmacologic interventions. The research found that biologic therapies have demonstrated efficacy in managing chronic antibiotic refractory pouchitis, offering a steroid-sparing option for refractory disease. Non-pharmacologic therapies, such as hyperbaric oxygen and fecal microbiota transplant, require further exploration. [Extracted from the article]

A recent study conducted at the University of Tsukuba in Japan explored the association between colonic metaplasia of goblet cells and endoscopic phenotypes of the J pouch in patients with ulcerative colitis (UC). The researchers found that patients with pouchitis showing colonic metaplasia of goblet cells may benefit from early interventions. The study also identified risk factors for diverting ileostomy in UC patients. The findings suggest that greater proportions of sulfomucin-producing goblet cells are observed in endoscopic phenotypes associated with poor outcomes in UC. [Extracted from the article]

A recent study conducted at the University of Ulsan in Korea investigated the risk factors and outcomes of chronic antibiotic-refractory pouchitis (CARP) in Korean patients with ulcerative colitis (UC). The study found that current smokers with UC who underwent total proctocolectomy with ileal pouch-anal anastomosis (IPAA) had a higher risk of developing CARP. Additionally, the use of probiotics was less likely to be associated with CARP development. The study highlights the importance of considering these risk factors and potential interventions for managing CARP in UC patients. [Extracted from the article]

A recent study conducted at Amsterdam University Medical Center explored the efficacy of tofacitinib in treating chronic pouchitis, a condition that affects some ulcerative colitis patients. Thirteen patients with chronic or antibiotic refractory pouchitis were treated with tofacitinib for eight weeks. The study found that 31% of patients achieved clinical remission, while 62% showed a clinical response. However, the study suggests that eight weeks of treatment may be too short to achieve biochemical, endoscopic, or histologic response in these refractory patients. Further research is needed to determine the optimal treatment duration. [Extracted from the article]

A recent study conducted at the University of Leuven in Belgium examined the long-term outcomes of patients with Crohn's disease who underwent modified side-to-side isoperistaltic strictureplasty (SSIS) to treat long strictures in the small intestine. The study aimed to determine if radiological features on MR enterography (MRE) could predict these outcomes. The researchers found that the Simplified MARIA (MARIAs) score, which assesses wall thickness, edema, fat stranding, and ulcers, was not predictive of long-term clinical or surgical recurrence. The study suggests that improvements are needed in scoring tools for predicting outcomes in these patients. [Extracted from the article]

A recent report from the University of North Carolina Chapel Hill discusses the findings of a study on ulcerative colitis. The study aimed to explore the relationship between clinical factors and the incidence of pouchitis, the most common complication after ileal pouch-anal anastomosis (IPAA) surgery for ulcerative colitis. The researchers found that antibiotic exposure in the 12 months prior to IPAA surgery was associated with an increased risk of acute pouchitis. This population-based cohort study suggests the need for future prospective studies to identify specific microbial changes in at-risk patients for earlier interventions. [Extracted from the article]

A recent study conducted at the Cleveland Clinic examined the outcomes of ileal-pouch anal anastomosis (IPAA) in patients with connective tissue disorders. IPAA is a surgical intervention commonly used for patients with ulcerative colitis, familial adenomatous polyposis, and indeterminate colitis. The study found that patients with connective tissue disorders were more likely to experience pouchitis, but there were no significant differences in rates of pouch prolapse or pouch failure compared to control patients. Overall, IPAA remains a viable surgical option for patients with connective tissue disorders, with comparable functional outcomes and quality of life. [Extracted from the article]

A study conducted at the University Hospital in Heraklion, Greece, examined the presence of inflammation in the terminal ileum, a common finding during colonoscopy, even in asymptomatic patients. The study aimed to determine the clinical importance and natural history of this condition, as well as the indications for treatment or follow-up. The retrospective cohort study analyzed data from 107 patients with terminal ileitis as an accidental finding, excluding those with symptoms or known Crohn's Disease. The study found that most patients with incidental, asymptomatic terminal ileitis remained asymptomatic and did not require treatment, but close monitoring is necessary as one-third of them were eventually diagnosed with Crohn's Disease. [Extracted from the article]

A recent study conducted at Weill Cornell Medicine compared two surgical techniques, Kono-S and side-to-side functional end anastomosis, for the treatment of Crohn's disease. The study found that both techniques had similar rates of endoscopic recurrence at 3-6 months after surgery. However, the study also found that smokers had a significantly higher rate of endoscopic recurrence. The research was a prospective multi-center randomized trial conducted at eight international centers and included 288 Crohn's patients. [Extracted from the article]

A recent study conducted by researchers at Washington University in St. Louis focused on ulcerative colitis (UC) and its complications. Specifically, the study examined a subset of patients who develop Crohn's-like disease of the pouch (CDP) after undergoing restorative proctocolectomy with ileal pouch-anal anastomosis (IPAA) for UC. The researchers used single-cell analyses to study mucosal cells from patients with and without CDP. The study found distinct cellular and molecular differences between normal pouch/ileum and CDP, including expanded colitogenic immune cells, elevated Th17 signaling, and increased levels of plasma cells, inflammatory fibroblasts, and monocytes in CDP. Additionally, the study identified extensive activation of the unfolded protein response (UPR) in CDP, which was not present in UC, Crohn's disease (CD), or pouchitis. The researchers suggest that these findings could potentially serve as diagnostic markers and therapeutic targets for CDP. [Extracted from the article]

A recent study conducted at the University Medical Center Rostock in Germany investigated the impact of ileitis on anastomotic healing after ileocecal resection (ICR) in a mouse model of Crohn's-like ileitis. The researchers found that mice with ileitis did not experience impaired healing of the anastomosis compared to control mice. However, mice with ileitis were more prone to microscopic abscess formation. The study suggests that ileitis alone is not a risk factor for impaired healing, and further research is needed to understand the effects of therapeutic immunomodulation on the healing process. [Extracted from the article]

A recent study conducted by researchers at Columbia University Medical Center explores the causes of pouchitis, a common condition that occurs after restorative proctocolectomy for ulcerative colitis. The researchers propose that inadequate mucus protection in the ileal pouch, combined with a predisposition to abnormal inflammation, is the most common cause of nonspecific pouchitis. The study highlights the lack of prior research on inadequate mucus protection and the origin of proctitis, and suggests that further studies on intestinal mucus in the ileal pouch and its association with pouchitis are needed. The full article can be accessed for free through the provided link. [Extracted from the article]

A recent study conducted at Copenhagen University Hospital Hvidovre in Denmark explored the use of allogenic faecal microbiota transplantation (FMT) as a treatment for chronic pouchitis, which is inflammation of the ileal pouch-anal anastomosis after proctocolectomy in the surgical treatment of ulcerative colitis. The researchers conducted a systematic review and meta-analysis of three randomized controlled trials (RCTs) involving 62 patients. The results showed that FMT was not superior to placebo in improving symptoms four weeks after treatment. However, the long-term effects of FMT on chronic pouchitis are still unknown. [Extracted from the article]